Loading...
•
Jun 30, 2021
Janux Q2 2021 Earnings Report
Janux reported financial results for the second quarter of 2021, marked by a successful IPO and advancements in the TRACTr platform.
Key Takeaways
Janux Therapeutics reported a net loss of $6.2 million for the second quarter of 2021. The company successfully completed a $222.9 million IPO in June, bringing total funds raised in the quarter to $347.9 million. Research and development expenses increased to $4.7 million, reflecting the development of the TRACTr platform technology and programs.
Completed a $222.9 million IPO in June, bringing total funds raised in the quarter to $347.9 million.
Cash and cash equivalents and short-term investments totaled $394.2 million as of June 30, 2021.
Research and development expenses for the quarter were $4.7 million.
Net loss for the quarter was $6.2 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...